Assessment of Aspirin Resistance in Patients with Recurrent Thrombotic Events by Thomas Xavier Paulsingh, J S
ASSESSMENT OF ASPIRIN RESISTANCE IN PATIENTS WITH 
RECURRENT THROMBOTIC EVENTS 
submitted in partial fulfillment of 
requirements for 
M.D. DEGREE BRANCH I GENERAL MEDICINE 
of 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
INSTITUTE OF INTERNAL MEDICINE 
MADRAS MEDICAL COLLEGE 
CHENNAI – 600 003 
APRIL – 2013 
  
CERTIFICATE 
This is to certify that the dissertation titled “ASSESSMENT OF 
ASPIRIN RESISTANCE IN PATIENTS WITH RECURRENT 
THROMBOTIC EVENTS” is a bona fide work done by Dr. J. S. 
THOMAS XAVIER PAULSINGH, Post Graduate Student, Institute of 
Internal Medicine, Madras Medical College, Chennai – 600003, in partial 
fulfillment of the university rules and regulations for the award of MD 
DEGREE in GENERAL MEDICINE BRANCH-I, under our guidance and 
supervision, during the academic period from April 2010 to April 2013. 
 
 
Prof. A. RADHAKRISHNAN, MD, 
Professor of Medicine, 
Institute of Internal Medicine, 
MMC and RGGGH 
Chennai – 600 003 
Prof. N. RAGHU, MD, 
Director and Professor, 
Institute of Internal Medicine, 
MMC and RGGGH 
Chennai – 600 003 
 
 
Prof. V. KANAGASABAI, MD, 
DEAN 
Madras Medical College and Rajiv Gandhi Government General Hospital, 
Chennai – 600 003. 
  
DECLARATION 
I solemnly declare that the dissertation titled “ASSESSMENT OF 
ASPIRIN RESISTANCE IN PATIENTS WITH RECURRENT 
THROMBOTIC EVENTS” was done by me at Madras Medical College, 
Chennai – 600003, during the period May 2012 to October 2012 under 
the guidance and supervision of Prof. A. RADHAKRISHNAN, MD, to 
be submitted to The Tamil Nadu Dr. M.G.R. Medical University towards 
the partial fulfillment of requirements for the award of MD DEGREE in 
GENERAL MEDICINE BRANCH-I. 
 
Place : Chennai 
Date : 26/12/2012 
Dr. J. S. THOMAS XAVIER PAULSINGH, 
MD GENERAL MEDICINE, 
Post Graduate Student, 
Institute of Internal Medicine, 
Madras Medical College, 
Chennai – 600003. 
  
ACKNOWLEDGEMENT 
I would like to thank our beloved Dean, Madras Medical College, 
Prof. V. KANAGASABAI, MD, for his kind permission to use the 
hospital resources for this study. 
I would like to express my sincere gratitude to my beloved 
Professor and Director, Institute of Internal Medicine, Prof. N. RAGHU, 
MD, for his guidance and encouragement. 
With extreme gratitude, I express my indebtedness to my beloved 
Chief, Prof. A. RADHAKRISHNAN, MD, for his motivation, advice and 
valuable criticism, which enabled me to complete this work. 
I am extremely thankful to Assistant Professors of Medicine,  
Dr. KALPANA RAMANATHAN, MD, Dr. SHARMILA, MD and  
Dr. HARIDOSS SRIPRIYA VASUDEVAN, MD, for their co-operation 
and guidance. 
I thank all Professors, Assistant Professors, and Post-graduates of 
Institute of Biochemistry, Department of Cardiology and Institute of 
Neurology for their valuable support in the analysis. 
I would always remember with extreme sense of thankfulness for 
the co-operation and criticism shown by my postgraduate colleagues. 
I am immensely grateful to the generosity shown by the patients 
who participated in this study. 
Above all I thank my God Almighty for His immense blessings and 
guidance. 
  
ABBREVIATIONS 
CAD Coronary artery disease 
CVA Cerebro vascular accident 
SHT Systemic hypertension 
DM Diabetes mellitus 
PPI Proton pump inhibitor 
BMI Body mass index 
HDL High density lipoprotein 
LDL Low density lipoprotein 
TGL Triglyceride 
11dhTxB2 11-dehydro thromboxane B2 
ESR Erythrocyte sedimentation rate 
  
TABLE OF CONTENTS 
1.  INTRODUCTION 1 
2.  AIMS AND OBJECTIVES 3 
3.  REVIEW OF LITERATURE 4 
4.  MATERIALS AND METHODS 36 
5.  OBSERVATIONS AND RESULTS 40 
6.  DISCUSSION 69 
7.  LIMITATIONS OF THE STUDY 74 
8.  CONCLUSION 75 
9.  BIBLIOGRAPHY 76 
10.  ANNEXURES 
 PROFORMA 80 
 INFORMATION SHEET 82 
 CONSENT FORM 83 
 ETHICAL COMMITTEE APPROVAL FORM 84 
 TURNITIN DIGITAL RECEIPT 85 
 ANTI-PLAGIARISM REPORT 86 
 MASTER CHART 87 
 
1 
 
INTRODUCTION 
Cardiovascular disease is a major cause of mortality and morbidity 
worldwide. Despite the development of newer antiplatelet drugs, aspirin 
is the most widely used antiplatelet drug to prevent first and recurrent 
myocardial infarcts and thrombotic cerebrovascular events including 
transient ischemic attacks. 
Over the last few years several studies have shown that the response 
to aspirin is not uniform among the patients. Nowadays the term aspirin 
resistance has been employed to express the occurrence of cardiovascular 
events in spite of regular intake of aspirin at recommended doses. 
Various studies have estimated the incidence of aspirin resistance 
to be 5 - 75%. It has been suggested that such patients have a three-fold 
higher risk of death, heart attack or stroke. Also 1 in 10 high risk patients 
suffer from the recurrence of a vascular event within the next 2 years 
despite regular daily aspirin therapy. 
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Urinary levels of the stable thromboxane metabolite, 11-dehydro 
thromboxane B2, reflect in vivo platelet activation and provide a 
surrogate marker of aspirin efficacy in patients on aspirin therapy. 
It can be used to identify patients at increased risk of recurrent 
cardiovascular events, and in such patients therapy with higher doses of 
aspirin or additional antiplatelet may be necessary to prevent further 
cardiovascular events after compliance to aspirin therapy has been 
ascertained. This study aims to assess the influence of aspirin resistance in 
the secondary prophylaxis of patients with recurrent cardiovascular 
diseases. 
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AIMS AND OBJECTIVES 
1. To assess the influence of aspirin resistance in the 
secondary prophylaxis of patients with recurrent 
thrombotic events 
2. To quantify aspirin resistance as a risk factor in failure of 
secondary prophylaxis 
3. To assess the prevalence of aspirin resistance in patients 
with recurrent thrombotic events 
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REVIEW OF LITERATURE 
Cardiovascular diseases are one of the most common non 
communicable diseases in the world. It includes any disease that affects 
the cardiovascular system, principally cardiac diseases, vascular diseases 
of brain and kidney and peripheral artery disease. Cardiovascular diseases 
are the most common cause of death worldwide. Most common cause of 
death in developed countries is heart diseases. Second most common 
cause of death in developed countries is cerebrovascular accident. They 
are more common in developed countries. The mortality rate due to 
cardiovascular disease is improved in developed countries for the past 
two decades. But the incidence of cardiovascular disease is also increased 
in developing countries. Cardiovascular diseases are the most common 
cause of death in some developing countries also. They are more common 
in males compared to females. Postmenopausal females have same risk 
for cardiovascular diseases compared to males. Old age people are more 
prone to have cardiovascular diseases. Now young people are also affected 
by cardiovascular diseases. The incidence of cardiovascular diseases in 
India is also increasing now because of adaptation with western diet. 
5 
 
The major types of cardiovascular diseases are coronary artery 
disease, cerebrovascular accident, peripheral artery disease, 
cardiomyopathy, valvular heart disease, systemic hypertension, cardiac 
dysrhythmias, inflammatory heart disease and heart failure. Among these 
coronary artery disease, cerebrovascular accident and peripheral vascular 
disease usually occur due to thrombotic pathology. Aspirin is the most 
commonly used drug to prevent these thrombotic events. 
CORONARY ARTERY DISEASE 
Ischemic heart disease usually occurs due to imbalance between 
myocardial oxygen supply and demand. It usually occurs due to 
inadequate blood supply to heart. Heart rate, myocardial contractility and 
myocardial wall tension are the three important factors determining 
myocardial oxygen demand. It is increased in anemia and also in left 
ventricular hypertrophy due to aortic stenosis. Due to myocardial 
ischemia, regional wall motion abnormalities will occur. The myocardial 
pumping function will be affected. Coronary heart disease can occur in 
infants who have are origin of left anterior descending coronary artery 
from pulmonary artery. 
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CEREBROVASCULAR ACCIDENT 
Cerebrovascular diseases include ischemic stroke, hemorrhagic 
stroke, intracranial aneurysm and AV malformation. Cerebrovascular 
accident is defined as acute onset of neurological deficit due to focal 
vascular cause. If cessation of blood flow lasts more than few seconds 
cerebral ischemia will occur. If cessation of blood flow lasts more than few 
minutes cerebral infarction will occur. Transient ischemic attack is 
defined as reversible focal neurological deficit without any radiological 
evidence of cerebral injury [1]. It must be reversible within twenty four 
hours. Symptoms in intracranial hemorrhage are due to mass affect and 
due to toxic effect of blood. 
PERIPHERAL ARTERY DISEASE 
Peripheral artery disease is a disease which is due to stenosis or 
occlusion of aorta or arteries of limbs. 
• Atherosclerosis (commonest cause) 
• Thrombosis 
• Embolism 
• Vasculitis 
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• Fibromuscular dysplasia 
• Entrapment 
• Cystic adventitial disease 
• Trauma. 
Diabetes mellitus, hypercholesterolemia, hypertension and 
hyperhomocysteinemia [2] are the risk factors for peripheral artery 
disease. 
ATHEROSCLEROSIS 
Atherosclerosis is the most common cause of cardiovascular 
diseases. Risk factors for atherosclerosis are: 
• Age 
• Gender 
• Smoking 
• Family history 
• Obesity 
• Lack of exercise 
• Psychosocial factors 
8 
 
Arterial remodeling occurs in atherosclerosis. In early stage of 
atherosclerosis the plaque usually grows outward. In later stage only it 
grows inward and results in stenosis. 
Atherosclerosis is usually a slow process. It usually begins in 
childhood and slowly progresses and manifests in old age. Precautions 
should be initiated in childhood to prevent atherosclerosis in old age. 
Causes of atherosclerosis in childhood are diabetes mellitus, nephrotic 
syndrome, chronic kidney disease, Kawasaki disease, childhood cancers, 
inflammatory bowel disease and certain types of congenital heart diseases. 
Clinical features of atherosclerosis are due to the following 
consequences: 
• Stenosis 
• Aneurysm formation 
Aorta is the most common site for development of aneurysm. 
Clinical feature due to atherosclerosis depends on the site of vessel 
involved. 
9 
 
• If it affects coronary arteries, myocardial infarction will 
occur. 
• If it affects the arteries supplying central nervous system, 
cerebral thrombosis will occur. 
• Atherosclerosis of peripheral arteries causes intermittent 
claudication and gangrene. 
• Atherosclerosis of splanchnic circulation causes mesenteric 
ischemia. 
• Atherosclerosis can affect kidney by causing stenosis of renal 
arteries. 
Epicardial coronary arteries are the most common site for coronary 
atherosclerosis. The severity of symptoms depends on the degree of 
stenosis. If the blood vessel is narrowed >50%, patient will develop chest 
pain at exertion. If the stenosis is >80%, patient will develop pain at rest. 
THROMBOSIS 
Thrombosis is the most common pathology seen in many 
cardiovascular diseases. Thrombosis is the pathological form of 
hemostasis. Hemostasis is a tightly regulated process. It maintains the 
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fluidity of blood in normal blood vessels. In thrombosis clot formation 
occurs in uninjured blood vessel and vessel may be occluded after 
relatively minor injury. Both hemostasis and thrombosis involve the 
following three components: 
• Vascular wall 
• Platelets 
• Coagulation cascade 
ENDOTHELIAL CELLS 
Normal endothelial cells maintain the fluidity of blood by 
inhibiting platelet adherence, preventing activation of coagulation factors 
and lysing blood clots. The sub endothelial extra cellular matrix is highly 
thrombogenic in nature. Normal endothelium inhibits exposure of 
platelets to the highly thrombogenic sub endothelial extra cellular matrix. 
Endothelial injury leads to exposure of underlying von Willebrand factor 
and basement membrane collagen to platelets. 
  
11 
 
PLATELETS 
After endothelial injury platelets adhere to the extra cellular matrix 
and bind with von Willebrand factor through GpIb receptor and become 
activated. ADP, TXA2, P-Selectin and calcium are secreted by activated 
platelets. ADP promotes further platelet aggregation. TXA2 increases 
further platelets activation and causes vasoconstriction. Calcium is 
essential for activation of coagulation factors. von Willebrand factor is 
essential for stabilization of factor VIII. It prolongs the half-life of factor 
VIII. ADP activates GpIIb-IIIa receptors in platelets and stimulates the 
formation of primary haemostatic plugs. 
COAGULATION CASCADE ACTIVATION 
Coagulation cascade activation is essential for formation of 
secondary hemostatic plug. Endothelial injury leads to release of tissue 
factor which initiate coagulation cascade. At the end of coagulation, 
thrombin converts fibrinogen to insoluble fibrin which helps to form 
secondary hemostatic plug. Blood coagulation scheme is classified into 
extrinsic and intrinsic pathways that converge with activation of factor X. 
Prothrombin time is used to assess the proteins involved in extrinsic 
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pathway. APTT is used to assess the proteins involved in intrinsic 
pathway. 
VIRCHOW’S TRIAD 
Three factors are essential for thrombus formation. This is called 
Virchow’s triad. They are: 
• Endothelial injury 
• Stasis or turbulence of blood flow 
• Hypercoagulability of blood 
The factors may act independently or in combination to promote 
thrombus formation. 
 
Figure 1: Virchow's triad 
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ENDOTHELIAL INJURY 
Endothelial injury may affect the normal blood flow and cause 
turbulent blood flow. It favors hypercoagulability of blood. Toxins, 
systemic hypertension, inflammation and metabolic products are 
responsible for endothelial injury. 
TURBULENCE OF BLOOD FLOW 
Abnormal blood flow may cause endothelial injury and initiate 
thrombus formation. Turbulence and stasis of blood contribute to 
thrombus formation. 
• Atherosclerotic plaque causes turbulence of blood flow 
• Aneurysm is responsible for stasis of blood 
• Mitral stenosis leads to stasis of blood in left atrium 
• Myocardial infarction leads to stasis of blood in left ventricle 
All these situations predispose to thrombus formation at their 
respective sites. 
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HYPERCOAGULABILITY 
Hypercoagulability generally contributes less frequently to 
thrombotic states but it nevertheless an important component for 
thrombus formation. 
Primary causes for hypercoagulable state: 
• Factor V Leiden mutation 
• Methyltetrahydrofolate gene mutation 
• Antithrombin III deficiency 
• Protein C deficiency 
• Protein S deficiency 
Secondary causes for hypercoagulable state: 
• Prolonged immobilization 
• Myocardial infarction 
• Atrial fibrillation 
• Tissue damage by surgery 
• Fracture 
• Burns 
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• Cancer 
• Prosthetic heart valve 
• Disseminated intravascular coagulation 
• Heparin induced thrombocytopenia 
• Antiphospholipid antibody syndrome 
• Nephrotic syndrome 
• Sickle cell anemia 
• Smoking 
• Pregnancy 
(Heparin induced thrombocytopenia is a hypercoagulable state 
despite having thrombocytopenia. Antiphospholipid antibody syndrome is 
also a hypercoagulable state despite having prolonged prothrombin time.) 
TYPES OF THROMBUS 
Thrombus may be formed anywhere in cardiovascular system – 
both arteries as well as veins. 
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ARTERIAL THROMBUS 
Arterial thrombi are usually formed at the site of endothelial injury. 
Arterial thrombi are formed by platelets and coagulation cascade 
activation. Arterial thrombi are usually superimposed on an 
atherosclerotic plaque. 
VENOUS THROMBUS 
Venous thrombi are usually formed at the site of stasis. Platelets 
may play very minimal role in venous thrombus formation. Venous 
thrombi usually occur in superficial or deep veins of leg. Superficial 
venous thrombi can cause congestion, swelling and pain. Deep venous 
thrombi are more prone for embolization. 
FATE OF THROMBUS 
Thrombi may propagate, resolve or embolize. 
• Propagation of thrombus leads to vessel obstruction 
• Dislodge of fragment of thrombi distal to circulation is called 
embolization 
• Thrombi may be resolved due to endogenous fibrinolytic 
system 
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ARACHIDONIC ACID 
Platelets are small irregularly shaped cells derived from 
megakaryocytes. They circulate in blood and involved in hemostasis 
leading to thrombus formation. Arachidonic acid which is a 20 carbon 
polyunsaturated fatty acid present in its esterified form as a component of 
cell membrane phospholipid. Products derived from arachidonic acid 
may affect thrombosis. Arachidonic acid is released from membrane 
phospholipids by phospholipase enzyme which is stimulated by 
mechanical, chemical or physical stimulus. Cyclooxygenase enzyme acts 
on arachidonic acid and it is responsible for generation of prostaglandins. 
Lipooxygenase enzyme acts on arachidonic acid and it is responsible for 
production of leukotrienes and lipoxins. 
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Figure 2: Conversion of arachidonic acid to prostaglandins and thromboxanes of series 2 
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PROSTAGLANDINS 
The type of prostaglandin generation usually depends on the cell in 
which it is formed: 
Platelets contain thromboxane synthase enzyme. If platelets are 
activated they produce thromboxane A2 through activation of 
thromboxane synthase enzyme. TXA2 has potent platelet aggregatory and 
vasoconstriction properties. 
If endothelial cells are stimulated they produce prostacyclins 
through activation of cyclooxygenase enzyme. Prostacyclins, PGE1, PGE2 
and PGD2 have vasodilatory property. TXA2, leukotriene C4, D4 and E4 
have vasoconstricting property. PAF is derived from membrane 
phospholipids by phospholipase A2. PAF causes vasoconstriction and 
bronchoconstriction. It also stimulates the synthesis of prostaglandins. 
Glucocorticoids act by inhibiting phospholipase A2 enzyme and 
preventing the release of arachidonic acid. This property is responsible 
for anti-inflammatory action of steroids. 
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There are three isoforms in COX enzyme: 
• COX 1 is a constitutive enzyme. It acts mainly in hemostasis 
and thrombus formation 
• COX 2 is an inducible enzyme. It is mainly involved in 
inflammation 
• COX 3 is a variant of COX 1 
ASPIRIN 
Aspirin is the most commonly used drug for secondary prevention 
of cardiovascular diseases. It is one of the cheapest drugs used in day 
today practice. Aspirin belongs to the group of non-steroidal anti-
inflammatory drugs. But aspirin differs from all other drugs by 
irreversibly inhibiting COX enzyme. Aspirin has antiplatelet, anti-pyretic 
and anti-inflammatory action. Antiplatelet action is due to inhibition of 
cyclooxygenase enzyme [3]. In addition to antiplatelet action, aspirin is 
responsible for increased formation of NO [4]. This property usually 
augments the anti-platelet property of aspirin to prevent cardiovascular 
diseases. 
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Figure 3: Ball-and-stick model of the aspirin molecule 
EFFECTS OF ASPIRIN 
Effects of aspirin depend on the dose in which it is used: 
• Low dose aspirin: 75-81 mg per day irreversibly inhibits 
platelet COX 1 enzyme. TXA2 synthesis alone impaired and 
responsible for antiplatelet effect. Platelets have life span of 7 
days. Antiplatelet action of aspirin lasts for 7 days. In other 
tissues synthesis of new COX enzyme replaces the 
inactivated enzymes so that ordinary doses have duration of 
6 - 12 hours. Platelet prostaglandin synthesis is inhibited 
completely by single dose of 100 mg aspirin or by 30 mg 
aspirin daily for 7 - 10 days. 
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• Intermediate dose: 650 mg - 4 g per day inhibits COX 1 and 
COX 2 enzymes and inhibits the synthesis of all 
prostaglandins. Intermediate dose has anti-pyretic and 
analgesic property. 
• High dose: 4 - 8 g per day has anti-inflammatory effect due to 
prostaglandin dependent (particularly COX 2 dependent 
PGE2) and independent effects. High dose aspirin is mainly 
used in rheumatic diseases. However the usefulness of high 
dose aspirin is limited by toxicity such as tinnitus, hearing 
loss and gastric upset. 
For antiplatelet action aspirin is usually used as once daily dose. 
For anti-inflammatory action in rheumatic diseases it is usually used as 
thrice daily dose. 
Low dose aspirin is enough to produce antiplatelet activity. 
Medium dose aspirin has no advantage over low dose aspirin to produce 
anti platelet action [5]. Low dose aspirin has more antiplatelet action than 
medium dose aspirin because low dose aspirin will not inhibit 
prostacyclin synthesis. Long term use of low dose aspirin for more than 
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five years is associated with lower incidence of colon cancer. The 
mechanism for this protective effect is not known. 
ASPIRIN INTOLERANCE 
Some people may develop hypersensitivity reaction to aspirin in the 
form of rhinitis, asthma and angioedema. Aspirin induced exacerbation 
of asthma is due to increased production of leukotrienes from 
arachidonic acid because of inhibition of cyclooxygenase pathway. 
Aspirin desensitization should be tried in these patients. The incidence of 
rhinitis and asthma due to aspirin intolerance is 10% and the incidence of 
angioedema is 0.07 - 2% [6-8]. If anti platelet activity is immediately 
needed in these patients, other antiplatelet drugs like clopidogrel can be 
tried. 
ADVERSE EFFECTS 
The adverse effects are generally similar for all NSAIDS: 
• Headache 
• Tinnitus 
• Dizziness 
• Proteinuria 
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• Thrombocytopenia 
• Abnormal liver function 
The adverse effects specific to aspirin in cardiovascular disease 
patients are gastric upset with bleed, worsening of heart failure and acute 
kidney injury. 
Gastro intestinal bleed 
Aspirin increases the risk of gastrointestinal bleed and rarely intra 
cranial bleed. Low dose aspirin has same risk to produce gastro intestinal 
bleed compared to higher dose [9-11]. If any antiplatelet drug or 
anticoagulant drug is added to aspirin the bleeding risk is increased. 
Males are more prone for gastro intestinal bleed compared to females. 
Patients who are having gastro intestinal ulcer are more prone to develop 
gastro intestinal bleed than others. 
The risk of gastro intestinal bleed is reduced with concomitant use 
of proton pump inhibitors. Proton pump inhibitors will not prevent 
lower gastro intestinal bleed [12]. The optimal regimen for patients who 
developed gastro intestinal bleed with low dose aspirin is to add a proton 
pump inhibitor rather than switching over to clopidogrel. 
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Congestive cardiac failure 
Intermediate dose of aspirin may precipitate congestive cardiac 
failure. It is due to inhibition of synthesis of vasodilatory prostaglandins 
which may increase blood pressure. Studies have shown that aspirin may 
attenuate the effect of ACE inhibitors. 
Acute kidney injury 
Prostaglandins improve the autoregulation of blood flow in 
kidneys. Aspirin inhibits the auto regulation and leads to renal 
vasoconstriction and acute interstitial nephritis. Aspirin may precipitate 
acute kidney injury. If aspirin is used with paracetamol the risk of chronic 
kidney disease is increased. Aspirin alone will not cause chronic kidney 
disease. 
CONTRAINDICATIONS 
Aspirin is contraindicated in hemophilia because of antiplatelet 
action. It is also contraindicated in children with viral fever due to the risk 
of Reye’s syndrome. Dose reduction should be done in both liver and 
renal failure. 
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Aspirin may prolong bleeding slightly not more than 1.2 - 2 times 
of pre-aspirin bleeding time. After discontinuation the bleeding time will 
become normal on fourth day and platelet aggregatory tests will become 
normal on eighth day. Aspirin must be stopped at least 1 week before 
surgery in surgical patients. Aspirin is rapidly converted into salicylic acid 
in the body. 
The ideal therapeutic serum salicylate concentration is 10 - 30 
mg/dl. Values greater than 40 mg/dl are associated with toxicity. 
OTHER ANTIPLATELET DRUGS 
Another antiplatelet drug clopidogrel which is a P2Y12 receptor 
blocker has some advantage over aspirin. It has less risk of gastro 
intestinal bleed and upset. Some studies have shown that it has more 
efficacy than aspirin. But compared to aspirin it is more expensive. 
Patients for whom cost is not an issue clopidogrel is probably better than 
aspirin for secondary prevention of cardiovascular diseases because of 
slightly greater efficacy and lesser side effects. 
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Dual antiplatelet therapy improves survival in acute coronary 
syndrome but it is not advised for cerebral thrombosis because of 
increased risk of intra cranial bleed. 
ASPIRIN FORMULATIONS 
There different types of aspirin formulations are available: 
• Regular 
• Buffered 
• Enteric coated 
Enteric coated aspirin will not disintegrate in stomach. So the risk 
of gastric upset is low with enteric coated aspirin [13]. Enteric coated 
aspirin has low bioavailability than regular aspirin because of reduced 
absorption in small intestine because of high pH. Low dose enteric coated 
aspirin has less anti platelet action compared to low dose regular aspirin 
[14-16]. Enteric coated aspirin should not be used as loading dose drug in 
acute myocardial infarction because of poor bio availability. 
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PREVENTION OF CARDIOVASCULAR DISEASES 
• Weight reduction 
• Smoking cessation 
• Mild alcohol intake 
• Hypertension control 
• Control of dyslipidemia and blood sugar 
• Good compliance with drugs like anti platelet drugs and 
anti-hypertensive drugs 
ASPIRIN RESISTANCE 
Clinical aspirin resistance is failure of aspirin to prevent recurrent 
thrombotic events despite regular intake of aspirin at regular interval [17-
22]. 
The term “laboratory aspirin resistance” is used to describe 
persistent platelet activation despite taking regular aspirin at regular 
interval [23-27]. 
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The incidence of laboratory aspirin resistance is highly variable 
depending upon the type of the test done and for whom the test is done. 
The incidence of aspirin resistance is 5 - 45% worldwide. 
GENETIC VARIABILITY 
Poor compliance with aspirin is the most common cause of aspirin 
resistance. Single nucleotide polymorphism is responsible for variable 
response to aspirin in aspirin taking patients. 
PROTON PUMP INHIBITORS 
Proton pump inhibitors may decrease the efficacy of aspirin. It may 
be due to decreased aspirin absorption in stomach due to elevated pH. 
Low pH is essential for absorption of aspirin. Würtz et al studied about 
the relationship between proton pump inhibitor and aspirin. They found 
that proton pump inhibitor may inhibit aspirin effect [28-30]. 
ATHEROSCLEROSIS 
Advanced atherosclerotic patients may have resistance to aspirin. 
In advanced atherosclerosis stimulation of COX 2 enzyme occurs from 
activated macrophages. TXA2 synthesis occurs through activation of 
COX 2 enzyme. This enzyme will not be inhibited by low dose aspirin. 
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CONCOMITANT INTAKE OF OTHER NSAIDS 
Concomitant intake with other NSAIDs may decrease the efficacy 
of aspirin. It is due to competitive inhibition in pharmacokinetics and 
pharmacodynamics of aspirin. Case control study from Physicians’ 
Health Study showed that concomitant use of NSAIDs for more than 60 
days per year may decrease the beneficial effects of aspirin. 
INCREASED PLATELET TURNOVER 
Increased platelet turnover is also a risk factor for aspirin 
resistance. In essential thrombocytosis once daily dose is not enough to 
inhibit the platelets. Twice daily dose may be advised in these patients. 
EARLY POST CABG PERIOD 
Aspirin resistance usually occurs in early post CABG period. It is 
due to the release of increased number of platelets from bone marrow in 
early post-operative period due to stress. 
DIABETES MELLITUS 
Diabetes mellitus is also a risk factor for aspirin resistance. Russo et 
al proposed that hyperglycemia interferes with aspirin induced NO 
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activation. This property is responsible for aspirin resistance in diabetes 
mellitus. Hyperglycemia will not interfere with thromboxane synthesis. 
Dillinger et al compared the efficacy of same dose of aspirin either 
once or twice daily in diabetes mellitus. They compared the efficacy of 
aspirin between 150 mg once daily taking patients and 75 mg twice daily 
taking patients. They found that twice daily dose was more effective than 
once daily dose. 
RENAL FAILURE 
Blann et al studied the relationship between aspirin resistance and 
renal function. Their study showed that patient having advanced renal 
dysfunction had more aspirin resistance than others. Aspirin may worsen 
renal failure. 
SMOKING 
Smoking is also a risk factor for aspirin resistance. Isoprostenes are 
prostaglandin F2 like components. They are produced from arachidonic 
acid which is COX independent. They induce vasoconstriction and have 
prothrombotic effects. Production of isoprostenes is directly proportional 
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to the number of cigarettes smoked. Smokers are more prone to develop 
aspirin resistance due to production of isoprostenes. 
OBESITY 
Obesity affects pharmacokinetics and pharmacodynamics of many 
drugs by changing body composition, regional blood flow, distribution of 
volume and clearance in kidney and liver. Rocca et al studied about the 
variable risk factors affecting the pharmacokinetics of aspirin. Their study 
showed that obesity was associated with decreased absorption of aspirin. 
Other risk factors for aspirin resistance are systemic hypertension 
and hypercholesterolemia. 
Al azzam et al performed study to find out the prevalence and risk 
factors for aspirin resistance. Their study showed that female gender and 
diabetes mellitus were risk factors for aspirin resistance. Their study also 
showed that statin therapy improved aspirin resistance. As per their study 
age, obesity, smoking, family history, dose and duration of aspirin intake 
were not related with aspirin resistance. 
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LABORATORY ASPIRIN RESISTANCE 
Laboratory aspirin resistance mostly correlates with clinical aspirin 
resistance. Grundman et al reported that 35% of clinically resistant 
patients had laboratory aspirin resistance and no clinically responsive 
patient had laboratory resistance. Anderson et al reported that 4.4% of 
biochemically sensitive patients had clinical resistance but 40% of 
biochemically resistant patients had clinical resistance. 
METHODS 
Several methods are available to estimate biochemical aspirin 
resistance. They will be discussed subsequently. 
URINARY TXB2 LEVEL ESTIMATION 
Measurement of TXA2 is not possible because of short half-life of 
TXA2. TXA2 is rapidly converted into TXB2. TXB2 excreted in the form 
of 11-dehydro thromboxane B2. High levels of urinary 11-dehydro 
thromboxane B2 are associated with aspirin resistance. Urinary TXB2 
level estimation is a simple method. It is well correlated with clinical 
events. 
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HOPE study showed that patients in upper quartile of 11-dehydro 
TXB2 excretion had more risk for occlusive thrombotic events. 
CHARISMA study also showed that patients who had high 11-
dehydro thromboxane B2 excretion had more risk for occlusive 
thrombotic events. 
P SELECTIN LEVEL ESTIMATION 
P Selectin is a protein stored in alpha granules in platelets which 
are not activated. If platelets are activated P Selectin is expressed in 
platelet surface after degranulation. Then P Selectin moves to plasma. 
Estimation of P Selectin indicates platelet activation. Patients who are 
having high serum P Selectin are more prone for occlusive thrombotic 
events. Two methods are available to estimate P Selectin level. P Selectin 
flow cytometry is more expensive than soluble P Selectin estimation, 
whereas soluble P Selectin estimation is simpler than P Selectin flow 
cytometry. 
PLATELET AGGREGATORY METHODS 
Platelet aggregation is induced in by adding adenosine 
diphosphate. Platelet function analyser 100 is clinically more relevant 
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than optical platelet aggregation tests because PFA 100 is performed in 
the presence of red blood cells and optical platelet aggregation test must 
be done in the absence of red cells. PFA 100 is a simple and rapid method 
compared to others. PFA 100 test is more expensive than others. It should 
be done within four hours after blood collection. It is less suitable for 
epidemiologic studies. Optical platelet aggregatory method is widely 
available but it is operator dependent. 
Aspirin resistant patients may be benefited from: 
• Rectifying the risk factors which are aggravating resistance 
• Increasing the dose of aspirin 
• Adding another anti platelet drug or omega 3 fatty acid 
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MATERIALS AND METHODS 
STUDY CENTER 
Institute of Internal Medicine, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai – 3. 
STUDY DESIGN 
Cross sectional study. 
PERIOD OF STUDY 
Study was conducted from June 2012 to November 2012 
SAMPLE SIZE 
• Cases: 40 
• Controls: 40 
INCLUSION CRITERIA 
• Age 18 to 65 years 
• On aspirin for more than 7 days 
EXCLUSION CRITERIA 
• Age <18 years and >65 years 
• Concomitant therapy with NSAIDs or anticoagulants 
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• History of active peptic ulcer 
• History of acute coronary syndrome during the previous seven 
days 
• Poor drug compliance 
• Thrombocytopenia  
• Thrombocytosis 
METHODOLOGY 
Forty patients with recurrent thrombotic events despite on aspirin 
therapy were selected as cases. Forty patients who were on aspirin 
following a cardiovascular event without any recurrence were selected as 
controls. 
Patients’ compliance with aspirin was checked. A complete history 
was taken either from the patient or his or her attender including past 
history of diabetes, hypertension, coronary artery disease and 
cerebrovascular accident. His or her personal habits were enquired. 
A complete physical examination was done with monitoring of 
vitals and anthropometry. A battery of blood investigations were done 
including renal function test, liver function test, complete blood count, 
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fasting lipid profile, fasting blood sugar, post prandial blood sugar, and 
thyroid function test. Other investigations included were ECG, 
echocardiogram and CT brain. 
Urine was collected from all the patients enrolled in the study and 
urinary levels of 11-dehydro thromboxane B2 were measured by 
Immunometric Assay using clinical chemistry analyzers. 
STATISTICAL ANALYSIS 
Data collected from the patients were analyzed using SPSS software 
version 21. The following tests were used to look for significance of the 
obtained results: 
• Chi-square test 
• Paired student t-test 
• ANOVA 
P value of <0.05 was considered as statistically significant at 95% 
confidence interval. 
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CONSENT 
Written informed consent was obtained from all the participants of 
the study 
ETHICAL COMMITTEE APPROVAL 
Institutional Ethics Committee of Madras Medical College 
approved the study 
CONFLICTS OF INTEREST 
Nil 
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OBSERVATIONS AND RESULTS 
CHARACTERISTICS OF THE STUDY POPULATION 
 Group Mean SD 
Age 
Cases 49.85 4.933 
Control 49.28 5.472 
Ht (cm) 
Cases 167.65 5.972 
Control 167.00 6.329 
Wt (kg) 
Cases 62.43 5.970 
Control 61.58 5.593 
BMI 
Cases 22.1935 1.56716 
Control 22.0547 1.27683 
FBS 
Cases 97.05 15.727 
Control 96.30 13.373 
PPBS 
Cases 141.30 30.512 
Control 139.65 26.639 
Cholesterol 
Cases 174.18 10.964 
Control 173.13 9.455 
HDL 
Cases 50.25 6.448 
Control 50.65 6.967 
TGL 
Cases 144.95 12.157 
Control 142.38 11.790 
LDL 
Cases 94.935 13.5338 
Control 94.000 12.5560 
Creatinine 
(mmol/l) 
Cases 80.8860 14.37306 
Control 83.7590 18.12628 
Duration of 
aspirin therapy 
Cases 3.30 0.966 
Control 3.05 0.904 
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PRIMARY EVENT 
Primary event Cases Controls Total 
CAD 30 31 61 
CVA 10 9 19 
Total 40 40 80 
 
 
 
SECONDARY EVENT 
CAD 27 
CVA 13 
 
0
5
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25
30
35
CAD CVA
Cases
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DURATION OF ASPIRIN THERAPY 
Duration of 
aspirin therapy 
[years] 
Cases Controls Total 
2 10 12 22 
3 12 17 29 
4 14 8 22 
5 4 3 7 
Total 40 40 80 
 
67%
33%
CAD
CVA
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URINARY 11-DH TXB2 LEVELS AMONG CASES AND CONTROLS 
Urinary 11-dh 
TxB2 levels 
n Mean SD 
Cases 40 26.93 0.840 
Controls 40 23.96 0.771 
 
0
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18
2 3 4 5
Cases
Controls
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Age group 
Age group 41-50 51-60 Total 
Cases 21 19 40 
Controls 24 16 40 
Total 45 35 80 
 
26.93
23.96
22 23 24 25 26 27 28
Cases
Controls
Mean
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0
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Cases Controls
41-50
51-60
Urinary 11-
dhTxB2 levels 
n Mean SD 
41-50 21 26.94 0.820 
51-60 19 26.91 0.882 
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41-50 years n Mean SD 
Cases 21 26.94 0.820 
Controls 24 24.03 0.761 
 
51-60 years n Mean SD 
Cases 19 26.91 0.882 
Controls 16 23.85 0.797 
  
26.89 26.9 26.91 26.92 26.93 26.94 26.95
41-50
51-60
Mean
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SEX 
Sex Male Female Total 
Cases 25 15 40 
Controls 23 17 40 
Total 48 32 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
Males 25 26.88 0.898 
Females 15 26.99 0.756 
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Male n Mean SD 
Cases 25 26.88 0.898 
Controls 23 23.99 0.728 
 
Female n Mean SD 
Cases 15 26.99 0.756 
Controls 17 23.90 0.844 
  
26.88
26.99
26.82 26.84 26.86 26.88 26.9 26.92 26.94 26.96 26.98 27
Males
Females
Mean
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SMOKING 
Smoking Smokers Non-smokers Total 
Cases 20 20 40 
Controls 17 23 40 
Total 37 43 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
Smokers 20 27.05 0.879 
Non-smokers 20 26.80 0.800 
 
0
5
10
15
20
25
Cases Controls
Smokers
Non-smokers
50 
 
 
 
Smokers n Mean SD 
Cases 20 27.05 0.879 
Controls 17 23.99 0.794 
 
Non-smokers n Mean SD 
Cases 20 26.80 0.800 
Controls 23 23.93 0.770 
  
26.65 26.7 26.75 26.8 26.85 26.9 26.95 27 27.05 27.1
Smokers
Non-smokers
Mean
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DIABETES 
Diabetes Diabetics Non-diabetics Total 
Cases 9 31 40 
Controls 7 33 40 
Total 16 64 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
Diabetics 9 26.77 1.074 
Non-diabetics 31 26.97 0.774 
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Diabetics n Mean SD 
Cases 9 26.77 1.074 
Controls 7 24.12 1.015 
 
Non-diabetics n Mean SD 
Cases 31 26.97 0.774 
Controls 33 23.92 0.724 
  
26.65 26.7 26.75 26.8 26.85 26.9 26.95 27
Diabetics
Non-diabetics
Mean
53 
 
HYPERTENSION 
Hypertension Hypertensives Normotensives Total 
Cases 27 13 40 
Controls 25 15 40 
Total 52 28 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
Hypertensives 27 26.98 0.883 
Normotensives 13 26.81 0.764 
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Hypertensives n Mean SD 
Cases 27 26.97 0.883 
Controls 25 23.84 0.827 
 
Normotensives n Mean SD 
Cases 13 26.82 0.764 
Controls 15 24.15 0.646 
  
26.7 26.75 26.8 26.85 26.9 26.95 27
Hypertensives
Normotensives
Mean
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PROTON PUMP INHIBITOR THERAPY 
PPI intake Present Absent Total 
Cases 32 8 40 
Controls 18 22 40 
Total 50 30 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
Present 32 26.96 0.852 
Absent 8 26.79 0.827 
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Patients on PPI n Mean SD 
Cases 32 26.97 0.852 
Controls 18 23.97 0.757 
 
Patients of PPI n Mean SD 
Cases 8 26.79 0.827 
Controls 22 23.95 0.800 
  
26.7 26.75 26.8 26.85 26.9 26.95 27
Present
Absent
Mean
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FAMILY HISTORY OF CARDIOVASCULAR DISEASE 
Family history Present Absent Total 
Cases 12 28 40 
Controls 9 31 40 
Total 21 59 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
Present 12 26.94 0.823 
Absent 28 26.92 0.861 
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Positive n Mean SD 
Cases 12 26.94 0.823 
Controls 9 24.04 1.070 
 
Negative n Mean SD 
Cases 28 26.92 0.861 
Controls 31 23.93 0.681 
  
26.91 26.915 26.92 26.925 26.93 26.935 26.94 26.945
Present
Absent
Mean
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SERUM CREATININE 
Serum creatinine 
[mmol/l] 
≤97.24 >97.24 Total 
Cases 35 5 40 
Controls 31 9 40 
Total 66 14 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
<97.24 35 26.93 0.852 
≥97.4 5 26.91 0.840 
 
0
5
10
15
20
25
30
35
40
Cases Controls
≤97.24
>97.24
60 
 
 
 
<97.24 mmol/l n Mean SD 
Cases 35 26.93 0.852 
Controls 31 23.89 0.766 
 
≥97.24 mmol/l n Mean SD 
Cases 5 26.91 0.840 
Controls 9 24.16 0.797 
  
26.9 26.905 26.91 26.915 26.92 26.925 26.93 26.935
<97.24
≥97.4
Mean
61 
 
BMI 
BMI [kg/m2] Cases Controls Total 
<23 30 33 63 
23-25 5 4 9 
>25 5 3 8 
Total 40 40 80 
 
 
Urinary 11-
dhTxB2 levels 
n Mean 
SD 
<23 30 27.04 0.770 
23-25 5 26.76 0.857 
>25 5 26.44 1.189 
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<23 n Mean SD 
Cases 30 27.04 0.770 
Controls 33 23.97 0.718 
 
23-25 n Mean SD 
Cases 5 26.76 0.857 
Controls 4 23.25 0.923 
 
>25 n Mean SD 
Cases 5 26.44 1.189 
Controls 3 24.74 0.365 
  
26 26.2 26.4 26.6 26.8 27 27.2
<23
23-25
>25
Mean
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FASTING BLOOD SUGAR 
FBS 
[mg/dL] 
Cases Controls Total 
<100 31 34 65 
100-125 4 3 7 
≥126 5 3 8 
Total 40 40 80 
 
 
Urinary 11-
dhTxB2 levels 
n Mean 
SD 
<100 31 26.98 0.774 
100-125 4 27.23 1.267 
>125 5 26.41 0.858 
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<100 n Mean SD 
Cases 31 26.97 0.774 
Controls 34 23.89 0.739 
 
100-125 n Mean SD 
Cases 4 27.23 1.267 
Controls 3 24.80 0.293 
 
≥126 n Mean SD 
Cases 5 26.41 0.858 
Controls 3 23.88 1.155 
  
26 26.2 26.4 26.6 26.8 27 27.2 27.4
<100
100-125
>125
Mean
Mean
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POST PRANDIAL BLOOD SUGAR 
PPBS 
[mg/dL] 
Cases Controls Total 
<140 32 34 66 
140-199 3 2 5 
≥200 5 4 9 
Total 40 40 80 
 
 
Urinary 11-
dhTxB2 levels 
n Mean 
SD 
<140 32 26.99 0.771 
140-199 3 26.09 1.512 
≥200 5 26.41 0.858 
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<140 n Mean SD 
Cases 32 26.99 0.771 
Controls 34 23.89 0.739 
 
140-199 n Mean SD 
Cases 3 27.09 1.512 
Controls 2 24.87 0.381 
 
≥200 n Mean SD 
Cases 5 26.41 0.858 
Controls 4 24.08 1.023 
 
25.6 25.8 26 26.2 26.4 26.6 26.8 27 27.2
<140
140-199
≥200
Mean
Mean
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LDL LEVEL 
LDL [mg/dL] Cases Controls Total 
<100 34 35 69 
≥100 6 5 11 
Total 40 40 80 
 
 
 
Urinary 11-
dhTxB2 levels 
n Mean SD 
<100 34 26.97 0.777 
≥100 6 26.66 1.188 
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<100 mg/dl n Mean SD 
Cases 34 26.97 0.777 
Controls 35 23.96 0.722 
 
≥100 mg/dl n Mean SD 
Cases 6 26.66 1.188 
Controls 5 23.91 1.167 
  
26.5 26.6 26.7 26.8 26.9 27
<100
≥100
Mean
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DISCUSSION 
Eighty patients were enrolled as our study population. Among 
them 40 patients were cases with recurrent cardiovascular events and the 
remaining 40 patients were controls with only one thrombotic event. 
CAD was the initial event in 30 cases (75%) and 31 controls 
(77.5%). CVA was the initial event in 10 cases (25%) and 9 (22.5%) 
controls. 
Among the cases, CAD was the recurrent event in 27 cases (67.5%) 
whereas CVA was the recurrent event in 13 cases (32.5%). 
Patients on longer duration of aspirin therapy showed more 
incidence of aspirin resistance. 22 cases and 29 controls were taking 
aspirin for ≤3 years whereas 18 cases and 11 controls were taking aspirin 
for >3 years. 
Mean urinary 11-dehydro thromboxane B2 level was 26.93 (SD = 
0.840) among cases and 23.96 (0.771) among controls (p <0.001) which 
was statistically significant. 
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AGE 
21 cases and 24 controls were in the age group of 41 – 50 years. 19 
cases and 16 controls were in the age group of 51 – 60 years. Age did not 
show any association with aspirin resistance (p = 0.88). Subgroup analysis 
also was not significant between cases and controls. 
SEX 
25 males and 15 females were in ‘case’ group and 23 males and 17 
females were in ‘control’ group. Sex was not associated with any 
significant difference in urinary levels of 11-dhTxB2 (p = 0.683). 
Subgroup analysis also showed no significant difference based on sex. 
SMOKING 
20 patients among cases and 17 patients among controls were 
smokers. Smoking was did not have any correlation with aspirin 
resistance (p = 0.350). 
DIABETES 
Among 16 diabetics in the study population, 9 patients were cases 
and 7 were controls. Presence of diabetes was not associated with any 
significant difference among cases (p = 0.547). Both diabetics as well as 
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non-diabetics showed significant difference between cases and controls 
whereas the difference between their means was not significant. 
HYPERTENSION 
27 cases and 25 controls were hypertensive. 13 cases and 15 
controls were normotensive. No significant difference was noted between 
these two groups (p = 0.576). 
PPI THERAPY 
32 cases and 18 controls were on proton pump inhibitor therapy. 
The mean difference between cases on PPI therapy and who were not on 
PPI therapy was not significant (p = 0.613). The mean difference was not 
significant between cases and controls also. 
FAMILY HISTORY 
In our study population, 21 patients had family history of 
cardiovascular disease (12 cases, 9 controls). Family history did not show 
any significant association with aspirin resistance among cases (p = 
0.962). 
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SERUM CREATININE 
Serum creatinine level was elevated more than 97.24 mmol/l in 5 
cases and 9 controls. Renal failure did not reveal any significant 
association with urinary levels of 11-dh TxB2 (p = 0.963). Subgroup 
analysis also revealed no significant difference between cases and 
controls. 
BMI 
30 cases (75%) and 33 controls (82.5%) had BMI less than 23. 5 
cases (12.5%) and 4 controls (10%) had BMI between 23 and 25. 5 cases 
(12.5%) and 3 controls (7.5%) had BMI above 25. Obesity was not 
associated with statistically significant difference among cases (p = 0.316) 
and between cases and controls. 
FASTING BLOOD SUGAR 
Fasting blood sugar was less than 100 mg/dl in 31 cases (77.5%) 
and 34 controls (85%). It was between 100 and 125 mg/dl in 4 cases (10%) 
and 3 controls (7.5%). Fasting hyperglycemia was seen in 5 cases (12.5%) 
and 3 control (7.5%). Fasting blood sugar level did not show any 
correlation with aspirin resistance. 
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POSTPRANDIAL BLOOD SUGAR 
Postprandial blood sugar was less than 140 mg/dl in 32 cases (80%) 
and 34 controls (85%); between 140 and 199 mg/dl in 3 cases (7.5%) and 2 
controls (5%); and ≥200 mg/dl in 5 cases (12.5%) and 4 controls (10%). 
Postprandial blood sugar was not associated with elevated urinary levels 
of 11-dh TxB2. 
LDL 
LDL level was less than 100 mg/dl in 34 cases (85%) and 35 
controls (87.5%) and it was ≥100 mg/dl in 6 cases (15%) and 5 controls 
(12.5%). No significant mean difference was noted among cases (p = 
0.403) as well as between cases and controls in terms of hyperlipidemia 
and aspirin resistance. 
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LIMITATIONS OF STUDY 
1. Coronary angiography was not done in all ischemic heart disease 
patients 
2. Patients were not classified based on whether they received 
thrombolysis or not 
3. Patients were not limited to same batch of aspirin on 
manufacturing basis 
4. Drug compliance was not assessed by estimating serum salicylate 
levels 
5. Test was not correlated with other platelet function assays 
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CONCLUSION 
1. Urinary 11-dehydro thromboxane B2 level estimation is a simple 
method 
2. Urinary 11-dehydro thromboxane B2 has been found to be 
significantly elevated in patients with recurrent thrombotic events 
3. Urinary 11-dehydro thromboxane level estimation should be 
considered in patients with recurrent thrombotic events to find out 
aspirin resistance 
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URINE 11-DEHYDRO THROMBOXANE B2 LEVELS AND ITS 
CORRELATION WITH ASPIRIN RESISTANCE IN PATIENTS 
WITH RECURRENT CARDIOVASCULAR EVENTS 
Name: Age/Sex: 
Address: Occupation: 
Symptoms: 
☐ Chest pain 
☐ Dyspnea 
☐ Weakness of limbs 
☐ Syncope 
☐ Giddiness 
☐ Any other drug intake 
Past history: 
☐ DM 
☐ SHT 
☐ CAD 
☐ Acid peptic disease 
☐ Renal failure 
Personal history: 
☐ Smoking 
☐ Alcoholism 
 
PHYSICAL EXAMINATION: 
General examination: 
 
Pulse: 
Blood pressure: 
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Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
 
INVESTIGATIONS: 
Hemogram RFT 
TC  cells/mm3 Glucose (F)  mg/dl 
DC  Glucose (PP)  mg/dl 
ESR  mm/hr Urea  mg/dl 
Hb  g/dl Creatinine  mg/dl 
PCV  % Na+  mEq/l 
Platelets  lakhs/mm3 K+  mEq/l 
RBCs  million/mm3  
Lipid profile TSH  
Total 
cholesterol 
 mg/dl Free T3  
LDL  mg/dl Free T4  
HDL  mg/dl Urine 11-
dehydrothromboxane 
B2 
 
Triglycerides  mg/dl 
 
 
ECG: 
 
ECHO CARDIOGRAM: 
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அல ககைள ெவளியி!" ேபாேதா அல ஆரா+சியி ேபாேதா 
த6கள ெபயைரேயா அல அைடயாள6கைளேயா ெவளியிடமா-ேடா" 
எபைத<" ெதாிவி ெகா5கிேறா". 
இத ஆரா+சியி ப6ேக ப த6க7ைடய விபதி ேபாி தா 
இகிற. ேம=" நீ6க5 எேநர8" இத ஆரா+சியி> பிவா6கலா" 
எபைத<" ெதாிவி ெகா5கிேறா". 
இத சிற# பாிேசாதைனகளி 89:கைள ஆரா+சியி ேபா அல 
ஆரா+சியி 89வி த6க7 அறிவிேபா" எபைத<" ெதாிவி 
ெகா5கிேறா". 
ஆரா+சியாள3 ைகெயாப" ப6ேக பாள3 ைகெயாப" 
ேததி: 
  
83 
 
ஆராசி ஒத கத 
ஆரா+சி தைல#: 
இரத ழா அைடபினா பாதி# ஏ ப-! ஆ.பிாி மாதிைர 
உ-ெகா0! வ" ெபா1" மீ0!" இரத ழா அைடபினா பாதி# 
ஏ ப!பவ3களிட" ஆ.பிாி மாதிைரயி ெசயல ற தைமயிைன றித 
ஆரா+சி.  
ெபய3:  ேததி: 
வய:  உ5ேநாயாளி எ0: 
பா:  ஆரா+சி ேச3ைக எ0: 
இத ஆரா+சியி விவர6க7" அத ேநாக6க7" 81ைமயாக என 
ெதளிவாக விளகப-ட. என விளகப-ட விஷய6கைள நா #ாி 
ெகா0! நா என ச"மதைத ெதாிவிகிேற. 
இரத ழா அைட# ப றி<", அதைன த!க பயப!தப!" 
ஆ.பிாி மாதிைர ம ," அத ெசயல ற தைமைய க0டறிய@9ய 
இரத பாிேசாதைனக5 றி" ஆரா+சியாள3 @ற 81வ" 
விள6கெப ேற. 
ேம ெகா0ட பாிேசாதைனயி ேபா ஏ பட@9ய பிவிைள:கைள<" 
81வ" உண3 இத பாிேசாதைன மனமார ச"மதிகிேற. 
ைகெயாப" 
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1 42 M Y N Y Y Y 174 62 20.48 89 123 172 48 139 96.2 79.56 2 CAD CAD 26.14 
2 56 M Y N N Y N 169 65 22.76 94 131 168 47 136 93.8 88.4 4 CAD CVA 27.86 
3 46 F N N Y Y N 159 52 20.57 88 119 174 53 138 93.4 70.72 4 CAD CVA 27.96 
4 47 M Y N N Y N 167 61 21.87 91 139 165 43 142 93.6 70.72 4 CVA CAD 26.29 
5 49 M N Y N N N 173 77 25.73 119 165 189 33 169 122.2 88.4 5 CAD CAD 25.41 
6 56 M Y Y N N Y 172 69 23.32 131 215 169 52 137 89.6 79.56 5 CVA CVA 25.88 
7 53 F N Y Y Y N 160 65 25.39 134 217 197 43 175 119.0 70.72 2 CAD CAD 26.63 
8 51 F N N Y Y Y 163 55 20.70 95 128 171 57 147 84.6 88.4 4 CAD CVA 26.95 
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9 43 M Y N Y Y N 173 68 22.72 96 134 170 48 142 93.6 79.56 2 CAD CVA 26.63 
10 48 F N N N Y N 162 53 20.20 88 126 171 51 149 90.2 79.56 4 CVA CAD 27.22 
11 57 F N N N N N 159 55 21.76 83 128 167 53 137 86.6 88.4 4 CAD CAD 27.48 
12 51 M Y Y Y Y N 170 74 25.61 123 180 191 35 171 121.8 88.4 3 CAD CAD 28.35 
13 45 M Y N Y Y N 169 61 21.36 84 123 166 43 134 96.2 70.72 4 CAD CAD 26.03 
14 56 M N N N Y N 168 60 21.26 88 116 166 57 138 81.4 70.72 4 CVA CAD 26 
15 51 M Y N Y Y Y 173 66 22.05 90 137 175 55 132 93.6 61.88 2 CAD CAD 27.94 
16 44 M Y N N N N 170 63 21.80 87 118 174 58 146 86.80 79.56 3 CAD CVA 27.46 
17 48 F N N Y Y N 160 57 22.27 93 135 165 52 132 86.6 88.4 3 CVA CAD 27.74 
18 52 M Y N Y Y N 175 69 22.53 96 127 164 52 138 84.4 79.56 3 CAD CAD 26.46 
19 49 M N N N Y N 173 65 21.72 91 129 174 49 148 95.4 79.56 4 CAD CVA 26.94 
20 55 F N Y Y Y Y 161 58 22.38 128 212 198 47 167 117.6 61.88 3 CAD CAD 27.74 
21 51 M N N Y Y N 171 63 21.55 84 118 168 59 143 80.4 70.72 2 CVA CVA 25.81 
22 42 F N N Y Y N 164 58 21.56 82 124 165 56 146 79.8 88.4 2 CAD CAD 25.44 
23 49 M Y N Y Y N 169 60 21.01 85 128 169 57 140 84.0 88.4 4 CAD CAD 28 
24 59 M Y Y N N Y 173 70 23.39 105 139 173 51 137 94.6 70.72 5 CVA CAD 27.65 
25 43 M Y N Y Y Y 167 59 21.16 92 130 168 54 134 87.2 61.88 2 CAD CVA 27.47 
26 47 M Y N Y Y Y 176 62 20.02 81 121 172 56 141 87.8 97.24 3 CVA CAD 26.93 
27 45 F N N Y Y N 158 55 22.03 95 132 178 58 139 92.2 70.72 4 CAD CAD 26.2 
28 56 M Y N Y Y N 175 63 20.57 92 136 173 47 147 96.6 79.56 3 CAD CAD 27.7 
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29 53 F N N Y Y N 164 57 21.19 92 126 171 52 134 92.2 79.56 4 CAD CVA 27.09 
30 56 M Y Y Y Y Y 170 75 25.95 133 216 205 38 177 131.6 61.88 2 CAD CAD 25.49 
31 51 M Y N Y Y N 173 69 23.05 85 125 172 43 148 99.4 97.24 3 CAD CAD 25.86 
32 43 F N Y N N Y 157 62 25.15 129 214 207 41 169 132.2 97.24 3 CAD CVA 26.33 
33 59 F N N Y Y N 164 58 21.56 82 116 167 55 141 83.8 88.4 5 CAD CAD 25.95 
34 51 F N Y Y Y N 159 59 23.34 110 141 163 52 145 82.0 141.44 3 CVA CAD 27.5 
35 47 M Y N N N N 178 69 21.78 84 119 168 49 142 90.6 79.56 2 CAD CAD 27.2 
36 53 M N N Y Y Y 168 65 23.03 92 129 170 47 136 95.8 79.56 3 CAD CAD 26.89 
37 50 M Y N Y Y N 169 59 20.66 94 137 169 55 137 86.6 61.88 4 CAD CVA 27.78 
38 41 F N N N N N 161 58 22.38 95 132 172 54 138 90.4 88.4 2 CVA CVA 26.91 
39 49 F N N Y Y Y 163 57 21.45 92 136 173 58 142 86.6 70.72 3 CAD CAD 27.83 
40 50 M Y N Y Y N 177 64 20.43 90 131 178 52 145 97.0 97.24 4 CAD CAD 27.93 
41 46 F N N Y Y N 156 52 21.37 88 120 172 57 147 85.6 70.72 3 CAD Nil 23.42 
42 49 M Y N Y Y N 173 65 21.72 94 139 170 59 134 84.2 79.56 4 CAD Nil 23.31 
43 56 M Y Y Y Y Y 168 72 25.51 130 216 190 34 172 121.6 79.56 3 CAD Nil 24.42 
44 51 M Y Y N N N 171 70 23.94 123 170 169 53 140 88.0 97.24 2 CVA Nil 24.6 
45 59 F N N Y Y N 162 56 21.34 96 128 168 55 138 85.4 79.56 3 CAD Nil 22.9 
46 41 M Y N Y Y N 175 64 20.90 87 123 172 54 132 91.6 88.4 2 CAD Nil 24.52 
47 44 M N N N N N 173 65 21.72 85 127 179 58 132 94.6 70.72 2 CAD Nil 23.3 
48 57 M Y N N N N 170 65 22.49 93 134 172 46 140 98.0 97.24 3 CVA Nil 23.05 
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49 50 F N N Y Y N 164 58 21.56 97 130 167 57 142 81.6 79.56 5 CAD Nil 23.6 
50 44 F N N Y Y N 159 56 22.15 95 137 163 51 135 85.0 79.56 3 CAD Nil 24.4 
51 60 M Y N Y Y Y 169 68 23.81 90 128 167 42 138 97.4 70.72 5 CAD Nil 23.06 
52 51 F N N N N N 159 53 20.96 83 124 176 53 133 96.4 61.88 4 CVA Nil 24.06 
53 58 M Y Y Y Y Y 169 73 25.56 126 211 203 35 175 133.0 97.24 3 CAD Nil 24.67 
54 50 M Y N Y Y N 174 64 21.14 95 134 174 49 139 97.2 88.4 4 CAD Nil 24.22 
55 45 F N N Y Y N 162 59 22.48 88 118 173 52 142 92.6 97.24 3 CAD Nil 24.15 
56 41 M N N Y Y Y 177 67 21.39 90 131 165 58 148 77.4 79.56 2 CAD Nil 23.55 
57 56 M Y N N N N 168 59 20.90 94 138 172 53 135 92.0 70.72 4 CAD Nil 23.78 
58 55 M N N Y Y N 174 65 21.47 95 128 172 46 131 99.8 70.72 3 CAD Nil 23.65 
59 51 F N Y Y N Y 165 60 22.04 129 213 165 58 137 79.6 150.28 3 CAD Nil 24.66 
60 46 F N Y N N N 158 63 25.24 115 145 195 45 169 116.2 79.56 2 CAD Nil 25.14 
61 43 M Y N Y N N 174 68 22.46 95 135 175 59 138 88.4 79.56 2 CAD Nil 24.29 
62 50 M Y N Y N N 175 62 20.24 91 134 172 52 134 93.2 61.88 5 CVA Nil 24.89 
63 42 F N N Y N N 163 61 22.96 90 132 178 52 143 97.4 88.4 2 CVA Nil 22.76 
64 49 F N N Y Y Y 165 59 21.67 96 125 167 56 137 83.6 88.4 4 CAD Nil 25.4 
65 54 M Y N N N N 173 67 22.39 87 116 163 43 144 91.2 97.24 2 CAD Nil 24.4 
66 51 F N N Y Y N 163 56 21.08 85 129 176 55 138 93.4 70.72 3 CAD Nil 24.03 
67 41 M N N N N N 171 64 21.89 90 129 172 48 143 95.4 61.88 2 CVA Nil 24.69 
68 44 F N N N N N 157 55 22.31 93 130 170 55 141 86.8 97.24 3 CAD Nil 23.88 
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69 50 F N N N Y N 159 54 21.36 91 136 168 52 138 88.4 88.4 3 CAD Nil 25.01 
70 52 M Y N Y N N 169 59 20.66 90 132 164 41 132 96.6 79.56 3 CAD Nil 23.69 
71 55 M Y Y Y N Y 171 68 23.26 98 140 191 36 168 121.4 141.44 3 CAD Nil 22.79 
72 49 M N N N Y N 170 62 21.45 88 124 162 58 139 76.2 70.72 4 CVA Nil 24.43 
73 51 F N Y Y N Y 160 59 23.05 133 217 194 44 171 115.8 70.72 2 CAD Nil 22.55 
74 43 M Y N Y Y N 174 63 20.81 83 123 168 44 136 96.8 70.72 3 CAD Nil 22.55 
75 49 F N N N N N 156 52 21.37 95 126 162 58 134 77.2 61.88 4 CVA Nil 23.08 
76 45 M Y N N N N 173 66 22.05 93 137 179 52 140 99.0 88.4 3 CAD Nil 24.52 
77 57 M Y N Y N Y 170 63 21.80 91 134 173 57 136 88.8 97.24 4 CVA Nil 25.23 
78 42 M N N N N N 172 64 21.63 86 130 170 42 148 98.4 88.4 2 CAD Nil 24.34 
79 49 F N N N N N 161 54 20.83 90 133 167 56 142 82.6 79.56 3 CAD Nil 23.97 
80 46 F N N Y N N 158 53 21.23 94 130 170 51 134 92.2 79.56 2 CAD Nil 23.31 
 
 
